TDM1 must be internalized by cancer cells after binding to HER2 to have an anti-tumor effect, and this receptor-mediated endocytosis primarily uses the clathrin-mediated (CME) internalization pathway (Kalim et al., 2017). The gene discussed is ERBB2; the disease is cancer.